key: cord-1043189-6h0p9927
authors: Razafimahatratra, Solohery Lalaina; Ndiaye, Mame Diarra Bousso; Rasoloharimanana, Lova Tsikiniaina; Dussart, Philippe; Sahondranirina, Paquerette Hanitriniala; Randriamanantany, Zely Arivelo; Schoenhals, Matthieu
title: Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors
date: 2021-09-14
journal: Lancet Glob Health
DOI: 10.1016/s2214-109x(21)00361-2
sha: 53bb77071018961a4c34f7c949330d4375cdde22
doc_id: 1043189
cord_uid: 6h0p9927

nan

Semi-quantitative indirect ELISA for detection of anti-SARS-CoV-2 Antibodies The ID Screen® SARS-CoV-2-N IgG Indirect ELISA (ID.Vet, Grabels, France) of semiquantitative type, demonstrates the antibodies (IgG) directed against the nucleocapsid (N) of the SARS -CoV-2 in human serum or plasma. Its use has been previously described 1 . In addition to the ID Screen kit, some samples were tested with the semi-quantitative WANTAI SARS-CoV-2 Ab ELISA (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.) kit. The WANTAI kit demonstrates the IgA, IgG, IgM antibodies directed against the Spike RBD antigen of SARS-CoV-2. These antibodies are more persistent and allow counting both recently infected patients and those infected almost a year ago. According to the manufacturer, the kit has a specificity of 100% and a sensitivity of 94.36%. We found a 95% Se at 6 months of diagnosis on an independent cohort (data not shown).

Luminex Xmap technology, a type of immunoassay that uses magnetic beads to simultaneously measure multiple analytes in a single experiment, was used to determine the presence of donor antibodies to ancestral or mutated variant proteins. Briefly, the samples to be tested were diluted to 1/100 and 100uL were distributed in the specific well and then, incubated with MAGPLEX COOH-microsphere beads (MC10012-01, Luminex) coupled either to ancestral proteins (SARS-CoV-2 Spike protein-RBD-HisTag, Z03483, GenScript) or to proteins comprising mutations specific to B.1.351 (SARS-CoV-2 (2019-nCoV) Spike RBD (K417N, E484K, N501Y)-HisRecombinant Protein, 40592-V08H85, SinoBiological, Beijing, P.R. China). After 30 min of incubation, magnetic microspheres were incubated 60s on magnet plate and washed with assay buffer (PBS 0.05%, BSA 0.1%, pH7.4). After a washing step, a phycoerythrin labelled protein G conjugate (H10104, Thermofisher, Massachusetts, U.S.) recognizing IgG is distributed into the wells. This binds to IgGs, forming an antigen-antibody-conjugate-PE complex. After removal of the excess conjugate by washing, the microplate is read in a Magpix instrument (MAGPX12234702, Texas, USA). The beads are then identified, and the PE fluorescence quantified. The amount of specific antibodies present in the sample is proportional to the intensity of fluorescence emitted. It is then possible for each sample to know whether the IgG binds more or less to ancestral RBD or to RBD containing mutations specific to B.1.351 calculating a RBD B.1.351 /RBD WT MFI ratio, and therefore predict exposure to B.1.351.

Sample collected in October 2020 were used for the calculation of the cutoff as variant B.1.351. was first identified in October 2020 after excluding an outlier (n=1) by Normality test (Shapiro-Wilk test). RBD B.1.351 /RBD WT MFI cut off values were determine using the "Mean + 3SD" formula (=0.58233785).

All recent seropositive samples (Anti-N IgG + ) from October to May 2021 were analyzed.

Analysis was using GraphPad Prism version 8.0 (GraphPad, La Jolla, CA). Statistical significance was calculated using chi square test, confidence intervals calculated using Wilson/Brown method.

This study was authorized by the Ministry of Health of Madagascar and by the BioMedical Research Ethics Committee (CERBM) that informed the investigators it required neither the approval of the committee nor specific donor consent (CERBM: IOR0000851) (Authorization N°205-MSANP/SG/AGMED/CERBM). Blood donors are advised their blood may be tested for surveillance purposes.

Affairs through the REPAIR COVID-19-Africa project coordinated by the Pasteur International Network association. WANTAI reagents were provided by WHO AFRO as part of a Sero-epidemiological "Unity" Study. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID and the United States Government. 

All authors declare no competing interests.

Data will be made available with publication (All data and deidentified participant age and gender) upon request to the corresponding author

We thank Pr André SPIEGEL for his comments that improved our correspondence and the blood donors of the NBTC in Antananarivo. We thank the Immunology of Infectious Diseases unit staff for performing assays.